Global Active Pharmaceutical Ingredients Market - Growth, Trends & Forecasts (2017 - 2022)

The global active pharmaceutical ingredients market was valued at USD 154 billion in 2015 and is projected to reach USD 225 billion by 2021, at a CAGR of 6.5% during the forecast period from 2016 to 2021. The impact of the pharmaceutical industry on active pharmaceutical ingredients is fueling the growth of this market.

Market Dynamics

The increasing adoption of biologicals and biosimilars and rising cancer prevalence are some of the factors that propel the growth of the pharmaceutical ingredients market. However, drug price control policies across various countries and fierce competition between the API manufacturers are turning out to be restraints for this market.

Market Segmentation

The market for active pharmaceutical ingredients is segmented by the business mode, type of synthesis, customer base, and geography.

Business Mode

Captive API

Merchant API

Type of Synthesis



Customer Base










About 41% of APIs were sold in the merchant market and generics comprised 43.5% of the total merchant market, in 2015. The branded drug segment accounted for the largest share, during the same year. The oncology segment is anticipated to grow at the highest rate in the coming years, due to the increasing prevalence of cancer, worldwide.


North America



Latin America

The Middle East and Asia

North America is currently the largest active pharmaceutical ingredients market, globally. Asia-Pacific is expected to emerge as the fastest growing region, due to low operation costs and high investments in medical research. Furthermore, the high cost of trained labor and energy are the most important factors that enforced European market to move its base to develop countries, such as India and China.

Many players in this market are trying to expand their product portfolio to top the global market. Few companies adopted product innovation as their key business strategy, to ensure their dominance in the market. TAPI and Dr. Reddyare the leading firms in this market.

The major players in the API market include -

Albemarle Corporation

Aurobindo Pharma

Boehringer Ingelheim GmbH

Dr. Reddy's Lab


Mylan N.V


Pfizer, Inc.

Ranbaxy Laboratories

Teva Active Pharmaceutical Industries Limited

Key Deliverables in the Study

Market analysis for the global active pharmaceutical ingredients market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers, restraints opportunities and challenges.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.

Identification and analysis of the macro and micro factors that affect the global active pharmaceutical ingredients market.

Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped

1. Introduction

1.1 Study Deliverables

1.2 Market Definition

1.3 General Study Assumptions

1.4 Report Description

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Timeline

2.4 Study Phases

2.4.1 Secondary Research

2.4.2 Discussion Guide

2.4.3 Market Engineering & Econometric Model

2.4.4 Expert Validation

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

5.1 Current Market Scenario

5.2 Porter's Five Forces

5.2.1 Bargaining Power of Suppliers

5.2.2 Bargaining Power of Consumers

5.2.3 Threat to New Entrants

5.2.4 Threat to Substitute Products and Services

5.2.5 Competitive Rivalry Within the Industry

6. Market Drivers, Restraints, Opportunities, and Challenges Analysis

6.1 Market Drivers

6.1.1 Huge Impact from Pharmaceutical Industry

6.1.2 Increasing Adoption of Biologicals and Biosimilars

6.1.3 Rising Prevalence of Cancer

6.2 Market Restraints

6.2.1 Drug Price Control Policies Across Various Countries

6.2.2 Fierce Competition Between the API Manufacturers

6.2.3 Stringent Regulations

6.3 Market Opportunities

6.4 Market Challenges

7. Market Segmentation

7.1 By Business Mode

7.1.1 Captive API

7.1.2 Merchant API

7.2 By Type of Synthesis

7.2.1 Synthetic

7.2.2 Biotech

7.3 By Customer Base

7.3.1 Generic

7.3.2 Branded

7.4 By Application

7.4.1 Cardiology

7.4.2 Pulmonology

7.4.3 Oncology

7.4.4 Ophthalmology

7.4.5 Neurology

7.4.6 Orthopedics

7.5 By Geography

7.5.1 North America USA Canada Mexico

7.5.2 Europe Germany France UK Italy Spain Scandinavia BENELUX Rest of Europe

7.5.3 Asia-Pacific Japan China India South Korea Australia & New Zealand Rest of Asia-Pacific

7.5.4 The Middle East & Africa GCC South Africa Rest of MENA

7.5.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape

8.1 Merger and Acquisition analysis

8.2 Collaborations and Partnerships

8.3 New Product Launches

9. Key Vendor Analysis

9.1 Albemarle Corporation

9.2 Aurobindo pharma

9.3 Boehringer Ingelheim GmbH

9.4 Dr. Reddy's Lab

9.5 Lupin

9.6 Mylan N.V

9.7 Novartis

9.8 Pfizer, Inc

9.9 Ranbaxy Laboratories

9.10 Teva Active Pharmaceutical Industries Limited

10. Future Outlook of the Market

Content are not available

Choose License Type